期刊
JOURNAL OF INORGANIC BIOCHEMISTRY
卷 102, 期 9, 页码 1731-1735出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2008.05.002
关键词
diorganotin(IV) complex; synthesis; structure characterization; antitumor activity
资金
- National Natural Science Foundation of China [30772682]
- New Century Excellent Talents in University of China [NCET-04-0258]
- Education Commission of Shanxi Province [200413]
- Science and Technology Commission of Shanxi Province of China [051105-2]
- Natural Science Foundation of Shanxi Province of China [2007021035]
- Science and Technology Commission Program [07010729, 07010792]
- Education Commission Program on Bringing New Ideas for Postgraduate Research of Shanxi Province of China [20061038]
Reaction of di-n-butyltin(IV) dichloride with 4-chlorobenzohydroxamic acid at 1:1 ratio yielded a new mixed-ligand diorganotin(IV) complex, di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride(DBDCT). It was fully characterized by IR, H-1, C-13, Sn-119 NMR spectra and single crystal X-ray analysis. In DBDCT, the tin atom is five-coordinated in a trigonal bipyramidal geometry. DBDCT exhibited strong in vitro cytotoxic activity toward human immature granulocyte leukemia (HL-60), human salivary-gland carcinoma (SGC-7901), human henrietta carcinoma (Hela) and human urinary bladder (T24) cell lines which, in some cases, were equal to, or even higher than those of cis-dichlorodiammineplatinum(II) (cisplatin, DDP), the widely clinically used drug. The further in vivo antitumor tests of DBDCT towards the transplantation tumor models of sarcoma carcinoma (S-180), hepatocellular carcinoma (H-22) and Ehrlich's ascites carcinoma (EAC) on mice were carried out via injection intraperitoneally with cisplatin as positive contrast drug. The results showed that DBDCT displayed in vivo antitumor activity against the hepatocellular carcinoma H-22 and sarcoma carcinoma S-180 which were close to those of cisplatin, meanwhile, the survival-extending rates at middle dose and high dose on mice Ehrlich's ascites tumor EAC were higher than those of cisplatin, and there was a good dose-effect relationship. (C) 2008 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据